Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma

European Journal of Endocrinology

Volumn 167, Issue 2, 2012, Pages 267-275

  Buffet, Camille ^a   Golmard, Jean Louis ^a   Hoang, Catherine ^a   Treásallet, Christophe ^a   Du Pasquier Feádiaevsky, Laurence ^a   Fierrard, Hélène ^a   Aurengo, André ^a   Menegaux, Fabrice ^a   Leenhardt, Laurence ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TUMOR BURDEN;

EID: 84864363159     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0105     Document Type: Article

References (38)

1. Hughes DT, Haymart MR, Miller BS, Gauger PG & Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011 21 231-236. (doi:10.1089/thy.2010.0137)
2. Hedinger C, Williams ED & Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989 63 908-911. (doi:10.1002/1097-0142 (19890301)63:5〈908::AID- CNCR2820630520〉3.0.CO;2-I)
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL & Trotti A. AJCC Cancer Staging Handbook. Springer-Verlag: New York, 2010.
4. Besic N, Pilko G, Petric R, Hocevar M & Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. Journal of Surgical Oncology 2008 97 221-225. (doi:10.1002/jso.20935)
5. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier C & Schlumberger M. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998 83 553-559. (doi:10.1002/(SICI)1097-0142(19980801)83:3〈553::AID-CNCR 25〉3.0.CO;2-U)
6. Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, Pearce EN, Braverman LE & Degli Uberti EC. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2171-2178. (doi:10.1210/jc.2005-2372)
7. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Bernante P, Pagetta C, Rampin L & Rubello D. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. European Journal of Surgical Oncology 2006 32 1144-1148. (doi:10.1016/j.ejso.2006.07.001)
8. Noguchi S, Yamashita H, Uchino S & Watanabe S. Papillary microcarcinoma. World Journal of Surgery 2008 32 747-753. (doi:10.1007/s00268- 007-9453-0)
9. Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M & Kawamoto H. Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Archives of Surgery 1996 131 187-191. (doi:10.1001/archsurg.1996.01430140077021)
10. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR & Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992 112 1139-1147.
11. Chow SM, Law SC, Chan JK, Au SK, Yau S & Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003 98 31-40. (doi:10.1002/cncr.11442)
12. Lo CY, Chan WF, Lang BH, Lam KY & Wan KY. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World Journal of Surgery 2006 30 759-766. (doi:10.1007/s00268-005-0363-8)
13. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ & Goellner JR. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008 144 980-988. (doi:10.1016/j. surg.2008.08.035)
14. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R & Barbieri V. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009 19 707-716. (doi:10.1089/thy.2008. 0270)
15. Kim TY, Hong SJ, Kim JM, Gu Kim W, Gong G, Ryu JS, Kim WB, Yun SC & Shong YK. Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer 2008 8 296. (doi:10.1186/1471-2407-8-296)
16. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L & Filetti S. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. Journal of Clinical Endocrinology and Metabolism 2010 95 4882-4888. (doi:10.1210/jc.2010-0762)
17. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, Filetti S & Trischitta V. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 60-63. (doi:10.1210/jc. 2005-1185)
18. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL & Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
19. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803. (doi:10.1530/eje.1.02158)
20. Roti E, Degli Uberti EC, Bondanelli M & Braverman LE. Thyroid papillary microcarcinoma: a descriptive and metaanalysis study. European Journal of Endocrinology 2008 159 659-673. (doi:10.1530/EJE-07-0896)
21. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D & Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 97 90-96. (doi:10.1002/cncr. 11031)
22. Pelttari H, Laitinen K, Schalin-Jantti C & Valimaki MJ. Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment. Clinical Endocrinology 2008 69 323-331. (doi:10.1111/j.1365-2265. 2008.03217.x)
23. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR & Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009 19 1043-1048. (doi:10.1089/thy.2008.0407)
24. Pisanu A, Reccia I, Nardello O & Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World Journal of Surgery 2009 33 460-468. (doi:10.1007/s00268-008-9870-8)
25. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K & Miya A. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World Journal of Surgery 2010 34 28-35. (doi:10.1007/s00268-009-0303-0)
26. Lombardi CP, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M & Raffaelli M. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World Journal of Surgery 2010 34 1214-1221. (doi:10.1007/s00268- 009-0375-x)
27. Tzvetov G, Hirsch D, Shraga-Slutzky I,Weinstein R, Manistersky Y, Kalmanovich R, Lapidot M, Grozinsky-Glasberg S, Singer J, Sulkes J, Shimon I & Benbassat C. Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. Thyroid 2009 19 487-494. (doi:10.1089/thy.2008.0228)
28. Lin JD, Chao TC, Hsueh C & Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Annals of Surgical Oncology 2009 16 2609-2616. (doi:10.1245/s10434-009-0565-7)
29. Tuttle RM & Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinology and Metabolism Clinics of North America 2008 37 419-435 (ix-x). (doi:10.1016/j.ecl. 2008.02.008)
30. Tuttle RM. Risk-adapted management of thyroid cancer. Endocrine Practice 2008 14 764-774.
31. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA & Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010 20 1341-1349. (doi:10.1089/thy.2010.0178)
32. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G & Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. European Journal of Endocrinology 2011 165 441-446. (doi:10.1530/EJE-11-0466)
33. Neuhold N, Schultheis A, Hermann M, Krotla G, Koperek O & Birner P. Incidental papillary microcarcinoma of the thyroidfurther evidence of a very low malignant potential: a Retrospective Clinicopathological Study with up to 30 years of follow-up. Annals of Surgical Oncology 2011 8 3430-3436.
34. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M & Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World Journal of Surgery 2010 34 1222-1231. (doi:10.1007/s00268-009-0359-x)
35. Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J & Ghossein R. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010 20 1085-1093. (doi:10.1089/thy.2010. 0174)
36. Moon HJ, Kim EK, Chung WY, Yoon JH & Kwak JY. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Annals of Surgical Oncology 2011 18 1916-1923.
37. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S & Goldstein DP. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America 2008 37 457-480. (doi:10.1016/j.ecl.2008.02.007)
38. Sacks W, Fung CH, Chang JT, Waxman A & Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010 20 1235-1245. (doi:10.1089/thy.2009.0455)